The CheckMate 040 was a clinical trial to evaluate the effect of nivolumab (anti-PD1 agents) plus ipilimumab (anti-CTLA-4 agents) for advanced HCC patients pretreated sorafenib (50). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.